Table 3.
Summarizes the significant changes to locomotor activity (Exp. 1) and DA efflux in the AcbSh (Exp. 2) between the different rat lines examined as well as the direction of change following NIC administration. Comparison groups are included. For time course changes in DA efflux (Exp. 2) please refer to figures 5 and 6.
| Rat Line | |||||||
|---|---|---|---|---|---|---|---|
| Dose: | Wistar | P | NP | HAD1 | LAD1 | HAD2 | LAD 2 |
| Acute NIC (i.p.) | Peripheral Injections (s.c.) of NIC - Locomotor Activity | ||||||
| Saline (Sal) | --- | --- | --- | --- | --- | --- | --- |
| 0.25 mg/kg | --- | ↑ NP | ↓ Sal | --- | --- | --- | --- |
| 0.5 mg/kg | --- | ↑ Sal; NP | ↓ Sal | ↑Sal, 0.25; LAD1 | --- | ↑Sal, 0.25; LAD2 | --- |
| Repeated NIC (i.p.) | |||||||
| Saline | --- | --- | --- | --- | --- | --- | ↓ Day 8–10 vs. 1–3 |
| 0.25 mg/kg | --- | --- | --- | --- | --- | --- | --- |
| 0.5 mg/kg | --- | ↑ Day 4, 7 T vs. 1; NP | --- | ↑ Sal, 0.25; Day 1–10; LAD1&2 | --- | ↑ Sal, 0.25; Day 8–10 vs. 1–2 LAD1&2 | ↑ Day 8–10 vs. 1–3 |
| Challenge NIC (i.p.) | |||||||
| Saline | --- | --- | --- | -- | --- | --- | --- |
| 0.25 mg/kg | --- | --- | --- | ↑ SAL | --- | ↑ SAL | ↑ SAL |
| 0.5 mg/kg | --- | ↑ NP | --- | ↑ SAL, 0.25; LAD1&2 | --- | ↑ SAL, 0.25 LAD1&2 | ↑ SAL |
| Concentration: | Microinjections of NIC in the pVTA - DA efflux in the AcbSh | ||||||
| aCSF | --- | --- | -- | --- | --- | --- | -- |
| 10 uM NIC | --- | ↑ Base; aCSF; Wistar | --- | ↑ Base; aCSF; LAD1 | --- | ↑ Base; aCSF; LAD2 | --- |
| 100 uM NIC | ↑ Base; aCSF | ↑ Base; aCSF | --- | ↑ Base; aCSF, 10; LAD1 | --- | ↑ Base; aCSF,10; LAD2 | ↑ Base; aCSF, 10 |
| 200 uM MC | ↑ Base; aCSF, 10 | ↑ Base; aCSF, 10, 100; Wistar | --- | --- | --- | --- | --- |